ProKidney Q3 2026: Wider Loss Signals a High-Stakes Trial Sprint

ProKidney reported a Q3 2026 loss of $0.17 per Class A share, missing expectations of $0.14. That gap traces almost entirely to a surge in research and development spending, which jumped to $40.8 million from $26.8 million a year earlier as the company accelerated enrollment in its pivotal Phase 3 PROACT 1 trial of rilparencel.

The R&D increase came largely from higher PROACT 1 clinical study and manufacturing costs, with the remainder tied to new hires supporting the trial. Enrollment has now expanded past 500 patients, up from the previous target of 470, with full enrollment expected to close in Q1 2027.

On the revenue side, the quarter offered a rare bright spot. ProKidney brought in $174 thousand, beating expectations, though that figure still represented a year-over-year decline of roughly 20%. For a clinical-stage company, the revenue line is a secondary concern compared to what the trial spending is trying to buy.

The critical number for investors is $141.9 million in cash and marketable securities, which management says funds operations only into mid-2027. That runway lands almost exactly when the pivotal eGFR slope topline data from an efficacy analysis set of approximately 320 patients are due in Q2 2027. A positive readout supports a bid for accelerated FDA approval; a negative one would leave the company with little financial cushion.

ProKidney has arranged a potential $200 million Class A share facility to address financing needs beyond mid-2027, and the confirmatory composite endpoint readout from the full 500-plus patient cohort is not expected until the second half of 2029. The company also presented eight abstracts at ASN Kidney Week 2026, including a pooled Phase 2 clinical analysis, as it builds the mechanistic case for rilparencel ahead of the pivotal readout. CEO Bruce Culleton described the PROACT 1 enrollment trajectory and Q2 2027 topline timing as on track.